Diagnosis and management of asthma in adults a review

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

IMPORTANCE Asthma affects about 7.5%of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. OBSERVATIONS Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-Acting β2-Agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-Acting β2-Agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-Acting β2-Agonists alone is not appropriate. Other controller approaches include long-Acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab). CONCLUSIONS AND RELEVANCE Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-Acting β2-Agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-Acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.

Original languageEnglish (US)
Pages (from-to)279-290
Number of pages12
JournalJAMA - Journal of the American Medical Association
Volume318
Issue number3
DOIs
StatePublished - Jul 18 2017

Fingerprint

Asthma
Adrenal Cortex Hormones
Biological Factors
Airway Obstruction
Muscarinic Antagonists
Bronchodilator Agents
Spirometry
Respiratory Sounds
Standard of Care
Biological Products
Cough
Respiratory System
Dyspnea
Allergens
Therapeutics
Referral and Consultation
Maintenance
Quality of Life
Inflammation
Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Diagnosis and management of asthma in adults a review. / McCracken, Jennifer; Veeranki, Sreenivas P.; Ameredes, Bill; Calhoun, William.

In: JAMA - Journal of the American Medical Association, Vol. 318, No. 3, 18.07.2017, p. 279-290.

Research output: Contribution to journalReview article

@article{b757003f19da4a1c82b130ee3fa76398,
title = "Diagnosis and management of asthma in adults a review",
abstract = "IMPORTANCE Asthma affects about 7.5{\%}of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. OBSERVATIONS Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-Acting β2-Agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-Acting β2-Agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-Acting β2-Agonists alone is not appropriate. Other controller approaches include long-Acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab). CONCLUSIONS AND RELEVANCE Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-Acting β2-Agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-Acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.",
author = "Jennifer McCracken and Veeranki, {Sreenivas P.} and Bill Ameredes and William Calhoun",
year = "2017",
month = "7",
day = "18",
doi = "10.1001/jama.2017.8372",
language = "English (US)",
volume = "318",
pages = "279--290",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Diagnosis and management of asthma in adults a review

AU - McCracken, Jennifer

AU - Veeranki, Sreenivas P.

AU - Ameredes, Bill

AU - Calhoun, William

PY - 2017/7/18

Y1 - 2017/7/18

N2 - IMPORTANCE Asthma affects about 7.5%of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. OBSERVATIONS Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-Acting β2-Agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-Acting β2-Agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-Acting β2-Agonists alone is not appropriate. Other controller approaches include long-Acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab). CONCLUSIONS AND RELEVANCE Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-Acting β2-Agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-Acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.

AB - IMPORTANCE Asthma affects about 7.5%of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. OBSERVATIONS Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-Acting β2-Agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-Acting β2-Agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-Acting β2-Agonists alone is not appropriate. Other controller approaches include long-Acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab). CONCLUSIONS AND RELEVANCE Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-Acting β2-Agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-Acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents.

UR - http://www.scopus.com/inward/record.url?scp=85025802077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025802077&partnerID=8YFLogxK

U2 - 10.1001/jama.2017.8372

DO - 10.1001/jama.2017.8372

M3 - Review article

VL - 318

SP - 279

EP - 290

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 3

ER -